JP2006509523A5 - - Google Patents

Download PDF

Info

Publication number
JP2006509523A5
JP2006509523A5 JP2004560854A JP2004560854A JP2006509523A5 JP 2006509523 A5 JP2006509523 A5 JP 2006509523A5 JP 2004560854 A JP2004560854 A JP 2004560854A JP 2004560854 A JP2004560854 A JP 2004560854A JP 2006509523 A5 JP2006509523 A5 JP 2006509523A5
Authority
JP
Japan
Prior art keywords
nucleic acid
cells
alphavirus
virus
alphavirus replicon
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2004560854A
Other languages
English (en)
Japanese (ja)
Other versions
JP4991108B2 (ja
JP2006509523A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2003/039723 external-priority patent/WO2004055166A2/en
Publication of JP2006509523A publication Critical patent/JP2006509523A/ja
Publication of JP2006509523A5 publication Critical patent/JP2006509523A5/ja
Application granted granted Critical
Publication of JP4991108B2 publication Critical patent/JP4991108B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2004560854A 2002-12-13 2003-12-12 多抗原性アルファウイルス・レプリコン粒子及び方法 Expired - Lifetime JP4991108B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US43329902P 2002-12-13 2002-12-13
US43305802P 2002-12-13 2002-12-13
US60/433,058 2002-12-13
US60/433,299 2002-12-13
PCT/US2003/039723 WO2004055166A2 (en) 2002-12-13 2003-12-12 Multi-antigenic alphavirus replicon particles and methods

Publications (3)

Publication Number Publication Date
JP2006509523A JP2006509523A (ja) 2006-03-23
JP2006509523A5 true JP2006509523A5 (enExample) 2007-02-08
JP4991108B2 JP4991108B2 (ja) 2012-08-01

Family

ID=32600124

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004560854A Expired - Lifetime JP4991108B2 (ja) 2002-12-13 2003-12-12 多抗原性アルファウイルス・レプリコン粒子及び方法

Country Status (8)

Country Link
US (2) US20040208848A1 (enExample)
EP (1) EP1585812B1 (enExample)
JP (1) JP4991108B2 (enExample)
AU (1) AU2003297039B2 (enExample)
CA (1) CA2509973C (enExample)
DK (1) DK1585812T3 (enExample)
ES (1) ES2618309T3 (enExample)
WO (1) WO2004055166A2 (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6783939B2 (en) * 2000-07-07 2004-08-31 Alphavax, Inc. Alphavirus vectors and virosomes with modified HIV genes for use in vaccines
US7045335B2 (en) * 2001-09-06 2006-05-16 Alphavax, Inc. Alphavirus replicon vector systems
EP1585812B1 (en) 2002-12-13 2017-01-18 Alphavax, Inc. Multi-antigenic alphavirus replicon particles and methods
KR101518309B1 (ko) 2003-03-20 2015-05-08 알파벡스, 인크. 개선된 알파바이러스 레플리콘 및 헬퍼 구축물
SI1629004T1 (sl) * 2003-06-05 2008-12-31 Wyeth Corp Imunogeni sestavki, ki vsebujejo vektorski replikon virusa venezuelskega konjskega encefalitisa in antigen za protein paramiksovirusa
EP1651666B1 (en) * 2003-07-11 2009-05-27 Alphavax, Inc. Alphavirus-based cytomegalovirus vaccines
ES2321212T3 (es) 2004-05-18 2009-06-03 Alphavax, Inc. Vectores alfavirus derivados de tc-83, particulas y metodos antecentes de la invencion.
ES2647491T3 (es) 2004-05-21 2017-12-21 Novartis Vaccines And Diagnostics, Inc. Vectores del alfavirus para las vacunas del virus de la gripe
EP1773402A2 (en) * 2004-06-17 2007-04-18 Mannkind Corporation Improved efficacy of immunotherapy by integrating diagnostic with therapeutic methods
US7862829B2 (en) * 2004-07-09 2011-01-04 University Of North Carolina At Chapel Hill Viral adjuvants
WO2007046839A2 (en) * 2005-02-15 2007-04-26 University Of North Carolina At Chapel Hill New live virus vaccines
ES2517869T3 (es) 2006-09-12 2014-11-04 Alphavax, Inc. Partículas de replicones de alfavirus emparejadas con antígenos proteicos como adyuvantes inmunológicos
AU2007342333B2 (en) 2006-09-12 2013-02-28 Alphavax, Inc. Alphavirus replicon particles encoding IL- 12 as immunological adjuvants
DK2183368T3 (en) 2007-06-21 2016-09-05 Alphavax Inc PROMOTER-FREE CASES FOR EXPRESSION OF ALPHAVIRUS STRUCTURE PROTEINS
AU2015249175A1 (en) * 2009-04-08 2015-12-10 Alphavax, Inc. Alphavirus Replicon Particles Expressing TRP2
US20120128714A1 (en) * 2009-04-08 2012-05-24 Wolchok Jedd D Alphavirus Replicon Particles Expressing TRP2
AU2011276234B2 (en) 2010-07-06 2016-02-25 Glaxosmithkline Biologicals S.A. Liposomes with lipids having an advantageous pKa- value for RNA delivery
SI2591114T1 (sl) 2010-07-06 2016-10-28 Glaxosmithkline Biologicals S.A. Imunizacija velikih sesalcev z majhnimi odmerki RNA
ES2646669T3 (es) 2010-07-06 2017-12-14 Glaxosmithkline Biologicals Sa Procedimientos de aumento de una respuesta inmunitaria mediante el suministro de ARN
WO2012031043A1 (en) 2010-08-31 2012-03-08 Novartis Ag Pegylated liposomes for delivery of immunogen-encoding rna
EP3520813B1 (en) * 2010-10-11 2023-04-19 GlaxoSmithKline Biologicals S.A. Antigen delivery platforms
WO2012058072A1 (en) 2010-10-27 2012-05-03 Harrisvaccines, Inc Method of rapidly producing vaccines for animals
US8822427B2 (en) 2010-10-27 2014-09-02 Harrisvaccines Methods and compositions to protect aquatic invertebrates from disease
US10004797B2 (en) 2010-10-27 2018-06-26 Harrisvaccines, Inc. Method of rapidly producing improved vaccines for animals
EP3854413A1 (en) * 2011-07-06 2021-07-28 GlaxoSmithKline Biologicals SA Immunogenic combination compositions and uses thereof
US20140271829A1 (en) * 2011-10-11 2014-09-18 Anders Lilja Recombinant self-replicating polycistronic rna molecules
EP2766385A2 (en) * 2011-10-12 2014-08-20 Novartis AG Cmv antigens and uses thereof
WO2014108515A1 (en) * 2013-01-10 2014-07-17 Novartis Ag Influenza virus immunogenic compositions and uses thereof
WO2015123592A2 (en) 2014-02-13 2015-08-20 Synthetic Genomics, Inc. Recombinant rna particles and methods of use
US10611800B2 (en) 2016-03-11 2020-04-07 Pfizer Inc. Human cytomegalovirus gB polypeptide
TW201907937A (zh) 2017-05-08 2019-03-01 美商葛利史東腫瘤科技公司 阿爾法病毒新抗原載體
SG11202005792RA (en) 2017-12-20 2020-07-29 Vlp Therapeutics Llc Alphavirus replicon particle
US11629172B2 (en) 2018-12-21 2023-04-18 Pfizer Inc. Human cytomegalovirus gB polypeptide
MX2021014525A (es) 2019-05-30 2022-03-17 Gritstone Bio Inc Adenovirus modificados.
EP4135847A4 (en) 2020-04-17 2024-05-15 VLP Therapeutics, Inc. Coronavirus vaccine
WO2021221127A1 (en) 2020-04-30 2021-11-04 Vlp Therapeutics, Inc. Cytokine immunotherapy
US11857622B2 (en) 2020-06-21 2024-01-02 Pfizer Inc. Human cytomegalovirus GB polypeptide
EP4192496A4 (en) 2020-08-06 2025-01-01 Gritstone bio, Inc. MULTIEPITOP VACCINE CASSETTES

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1247080A (en) * 1983-03-08 1988-12-20 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
US4650764A (en) * 1983-04-12 1987-03-17 Wisconsin Alumni Research Foundation Helper cell
US5091309A (en) * 1986-01-16 1992-02-25 Washington University Sindbis virus vectors
NZ225583A (en) * 1987-08-06 1991-07-26 Merck & Co Inc Process for purifying hepatitis a virions (hav)
US5217879A (en) * 1989-01-12 1993-06-08 Washington University Infectious Sindbis virus vectors
US5185440A (en) 1989-06-20 1993-02-09 North Carolina State University cDNA clone coding for Venezuelan equine encephalitis virus and attenuating mutations thereof
US6770283B1 (en) * 1990-12-13 2004-08-03 Bioption Ab DNA expression systems based on alphaviruses
SE9003978D0 (sv) * 1990-12-13 1990-12-13 Henrik Garoff Dna expressionssystem baserade paa ett virus replikon
AU6172194A (en) * 1993-02-08 1994-08-29 Paravax, Inc. Defective sindbis virus vectors that express (toxoplasma gondii) p30 antigens
US20020102273A1 (en) * 1995-08-08 2002-08-01 Robert B. Grieve Use of alphavirus expression vectors to produce parasite anitgens
US6015686A (en) * 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
EP0711829A3 (en) 1993-09-15 1997-07-09 Viagene Inc Recombinant alphavirus vector
SE9401091D0 (sv) 1994-03-31 1994-03-31 Bioption Ab Alphavirus cDNA vectors
SE9401709D0 (sv) 1994-05-18 1994-05-18 Mathilda Sjoeberg Improved alphavirus vectors for expression of heterologous DNA
US6309642B1 (en) * 1997-04-28 2001-10-30 The Research And Development Institute, Inc. Peptides which mimic candida carbohydrate epitopes and their use in a vaccine
US5505947A (en) 1994-05-27 1996-04-09 The University Of North Carolina At Chapel Hill Attenuating mutations in Venezuelan Equine Encephalitis virus
IL113817A (en) * 1994-06-30 2001-03-19 Merck & Co Inc Polynucleotide vaccne for papillomavirus
WO1996017072A2 (en) 1994-11-30 1996-06-06 Chiron Viagene, Inc. Recombinant alphavirus vectors
US5703057A (en) 1995-04-07 1997-12-30 Board Of Regents The University Of Texas System Expression library immunization
US5639650A (en) 1995-05-23 1997-06-17 The University Of North Carolina At Chapel Hill cDNA clone for South African Arbovirus No. 86
US5792462A (en) * 1995-05-23 1998-08-11 University Of North Carolina At Chapel Hill Alphavirus RNA replicon systems
US5840839A (en) * 1996-02-09 1998-11-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein
US6451592B1 (en) * 1996-04-05 2002-09-17 Chiron Corporation Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
US5853719A (en) 1996-04-30 1998-12-29 Duke University Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA
CZ438398A3 (cs) * 1996-07-01 1999-03-17 Rhone-Poulenc Rorer S. A. Způsob přípravy rekombinantních adenovirů
US6235290B1 (en) * 1997-07-11 2001-05-22 University Of Manitoba DNA immunization against chlaymdia infection
US5827658A (en) 1996-08-09 1998-10-27 The United States Of America As Reprsented By The Department Of Health And Human Services Isolation of amplified genes via cDNA subtractive hybridization
US5726022A (en) * 1996-11-18 1998-03-10 Lifespan Biosciences, Inc. Subtractive hybridization and capture methods and kits for differential isolation of nucleic acids including disease-associated sequences
WO1998022588A2 (en) * 1996-11-20 1998-05-28 Introgen Therapeutics, Inc. An improved method for the production and purification of adenoviral vectors
US5811407A (en) * 1997-02-19 1998-09-22 The University Of North Carolina At Chapel Hill System for the in vivo delivery and expression of heterologous genes in the bone marrow
US5958738A (en) 1997-03-24 1999-09-28 Roche Diagnostics Corporation Procedure for subtractive hybridization and difference analysis
US6261570B1 (en) * 1997-05-20 2001-07-17 The United States Of America As Represented By The Secretary Of The Army Live attenuated virus vaccines for western equine encephalitis virus, eastern equine encephalitis virus, and venezuelan equine encephalitis virus IE and IIIA variants
AUPO856097A0 (en) 1997-08-14 1997-09-04 Commonwealth Scientific And Industrial Research Organisation Vector
US6197502B1 (en) * 1997-11-17 2001-03-06 Cytos Biotechnology Ag Expression cloning processes for the discovery characterization, and isolation of genes encoding polypeptides with a predetermined property
GB9804632D0 (en) * 1998-03-05 1998-04-29 Cantab Pharma Res Virus preparations and methods
AU754320B2 (en) 1998-04-08 2002-11-14 University Of North Carolina At Chapel Hill, The Methods and modified cells for the treatment of cancer
US6844188B1 (en) * 1998-04-08 2005-01-18 University Of North Carolina At Chapel Hill Methods and modified cells for the treatment of cancer
EP1080218A1 (en) * 1998-05-27 2001-03-07 University of Florida Method of preparing recombinant adeno-associated virus compositions by using an iodixanol gradient
WO2000000616A2 (en) * 1998-06-29 2000-01-06 U.S. Medical Research Institute Of Infectious Diseases Marburg virus vaccines
ATE382693T1 (de) * 1998-07-10 2008-01-15 U S Army Medical Res Inst Of I Impfstoffe gegen neurotoxine von clostridium botulinum
DE69940157D1 (en) * 1998-07-10 2009-02-05 U S Medical Res Inst Of Infect Anthrax-impfstoff
US6770479B1 (en) * 1998-07-10 2004-08-03 The United States Of America As Represented By The Secretary Of The Army Anthrax vaccine
AU6289699A (en) 1998-10-05 2000-04-26 Genzyme Corporation Genes differentially expressed in cancer cells to design cancer vaccines
US6329201B1 (en) * 1998-12-31 2001-12-11 Chiron Corporation Compositions and methods for packaging of alphavirus vectors
WO2000039318A1 (en) 1998-12-31 2000-07-06 Chiron Corporation Compositions and methods for packaging of alphavirus vectors
DK1175497T3 (da) 1999-04-14 2010-05-31 Novartis Vaccines & Diagnostic Præparater og fremgangsmåder til generering af et immunrespons ved udnyttelse af alfavirusbaserede vektorsystemer
AU2001275191A1 (en) * 2000-05-31 2001-12-11 Chiron Corporation Method for the purification of alphavirus replicon particles
US6783939B2 (en) * 2000-07-07 2004-08-31 Alphavax, Inc. Alphavirus vectors and virosomes with modified HIV genes for use in vaccines
US6982087B2 (en) 2000-09-07 2006-01-03 The University Of North Carolina At Chapel Hill Vectors derived from South African Arbovirus No. 86
AU2002305914A1 (en) * 2001-01-12 2002-10-21 Chiron Corporation Nucleic acid mucosal immunization
AU2002303330B2 (en) * 2001-05-31 2008-07-24 Novartis Vaccines And Diagnostics, Inc. Chimeric alphavirus replicon particles
US7045335B2 (en) * 2001-09-06 2006-05-16 Alphavax, Inc. Alphavirus replicon vector systems
US6936427B2 (en) * 2002-02-08 2005-08-30 Trellis Bioscience, Inc. Real time detection of intermolecular interaction
US6943015B2 (en) * 2002-12-12 2005-09-13 Ilya Frolov Large scale production of packaged alphavirus replicons
EP1585812B1 (en) 2002-12-13 2017-01-18 Alphavax, Inc. Multi-antigenic alphavirus replicon particles and methods
JP5079981B2 (ja) * 2002-12-13 2012-11-21 アルファバックス，インコーポレイティド アルファウイルス粒子及び調製方法
KR101518309B1 (ko) 2003-03-20 2015-05-08 알파벡스, 인크. 개선된 알파바이러스 레플리콘 및 헬퍼 구축물
US20060099587A1 (en) 2003-06-20 2006-05-11 Johnston Robert E Alphavirus vectors having attentuated virion structural proteins
EP1651666B1 (en) * 2003-07-11 2009-05-27 Alphavax, Inc. Alphavirus-based cytomegalovirus vaccines
ES2321212T3 (es) 2004-05-18 2009-06-03 Alphavax, Inc. Vectores alfavirus derivados de tc-83, particulas y metodos antecentes de la invencion.
US20120128714A1 (en) * 2009-04-08 2012-05-24 Wolchok Jedd D Alphavirus Replicon Particles Expressing TRP2

Similar Documents

Publication Publication Date Title
JP2006509524A5 (enExample)
Ye et al. Current status of COVID‐19 (pre) clinical vaccine development
CA2567254A1 (en) Tc-83-derived alphavirus vectors, particles and methods
JP2010530245A5 (enExample)
Samsa et al. Self-amplifying RNA vaccines for Venezuelan equine encephalitis virus induce robust protective immunogenicity in mice
Tatsis et al. Adenoviruses as vaccine vectors
WO2003048348A3 (en) Production of viruses, viral isolates and vaccines
JP2005523318A5 (enExample)
JP2004501647A5 (enExample)
CA2509973C (en) Multi-antigenic alphavirus replicon particles and methods
HRP20221474T1 (hr) Cjepiva protiv virusa hepatitisa b
WO2002000885A3 (en) Assembly of wild-type and chimeric influenza virus-like particles (vlps)
US20210254021A1 (en) Integrated manufacturing and chromatographic system for virus production
RU2012140691A (ru) Вакцины на основе неинтегрирующегося ретровирусного вектора
WO2005035556A3 (en) Sars-coronavirus virus-like particles and methods of use
WO2008115199A3 (en) Chimeric virus vaccines
Rezaei et al. Recent advances on HIV DNA vaccines development: Stepwise improvements to clinical trials
JP2025169275A5 (enExample)
RU2009144980A (ru) Рецептура растворов сахаров для непрерывного ультрацентрифугирования для очистки вирусов
CN116218879A (zh) 一种单价广谱的正痘病毒属mRNA疫苗及其应用
WO2003031583A3 (en) Generation of virus-like particles by vsv
CY1107431T1 (el) Σωματιδια για γoνιδιακη θεραπεια
CN102127554B (zh) 一种日本脑炎颗粒疫苗及其制备方法和应用
JP2009522368A5 (enExample)
CN114438079B (zh) 一种仿病毒dna多面体框架结构及其制备方法与应用